Menu
Back to User profile » Mr Francesco Patalano
Papers published by Mr Francesco Patalano:
Performance of the Cough and Sputum Assessment Questionnaire (CASA-Q) in COPD: Evidence from Clinical and Online Patient Interaction Studies
Patalano F, Hache C, Pethe A, Kaur H, Leidy NK, Arsiwala T, Afroz N, Gutzwiller FS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:3087-3096
Published Date: 10 December 2022
Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients
Kostikas K, Mackay AJ, Vogelmeier CF, Frent SM, Gupta P, Banerji D, Patalano F, Pfister PJ, Wedzicha JA
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:1831-1838
Published Date: 28 July 2020
Patient-Reported Outcomes (PROs) in COPD Clinical Trials: Trends and Gaps
Afroz N, Gutzwiller FS, Mackay AJ, Naujoks C, Patalano F, Kostikas K
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:1789-1800
Published Date: 23 July 2020
Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study
Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1229-1237
Published Date: 16 April 2018
Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study
Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1125-1134
Published Date: 10 April 2018
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:907-922
Published Date: 17 March 2017
Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study
Wedzicha JA, Zhong N, Ichinose M, Humphries M, Fogel R, Thach C, Patalano F, Banerji D
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:339-349
Published Date: 19 January 2017
Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
Vogelmeier C, Zhong NS, Humphries MJ, Mezzi K, Fogel R, Bader G, Patalano F, Banerji D
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:3189-3197
Published Date: 14 December 2016
The asthma–COPD overlap syndrome: do we really need another syndrome in the already complex matrix of airway disease?
Kostikas K, Clemens A, Patalano F
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:1297-1306
Published Date: 16 June 2016
Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study
LaForce C, Feldman G, Spangenthal S, Eckert JH, Henley M, Patalano F, D’Andrea P
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:1233-1243
Published Date: 8 June 2016
LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD
Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1015-1026
Published Date: 5 June 2015